Refractory psoriatic arthritis: A clinical case study of successful risankizumab therapy
https://doi.org/10.34215/1609-1175-2026-1-83-86
Abstract
This article presents a clinical case of psoriatic arthritis (PsA). Its focus is on the efficacy of risankizumab (RIS), an IL-23 inhibitor, in treating a patient with highly active PsA who did not respond to standard therapy. It was demonstrated that RIS is highly effective through the clinical remission of skin manifestations and a significant reduction in arthritis activity. Thus, these results confirm the importance of biological therapy and the treat-to-target strategy.
About the Authors
A. A. Sinenko
Pacific State Medical University; Primorsky Regional Clinical Hospital № 1
Russian Federation
Russian Federation
Andrey A. Sinenko – Cand. Sci. Med.), Associate Professor of the Institute of Therapy and Instrumental Diagnostics of the Pacific Medical University.
2, Ostryakova ave., 690106, Vladivostok
tel.: +7 (914) 670-33-54
N. M. Lupach
Primorsky Regional Clinical Hospital № 1
Russian Federation
Russian Federation
Vladivostok
O. I. Syusina
Primorsky Regional Clinical Hospital № 1
Russian Federation
Russian Federation
Vladivostok
E. A. Zinkova
Far Eastern Federal University
Russian Federation
Russian Federation
Vladivostok
References
1. Azuaga AB, Ramírez J, Cañete JD. Psoriatic Arthritis: Pathogenesis and Targeted Therapies. International Journal of Molecular Sciences. 2023;24(5):4901. doi: 10.3390/ijms24054901
2. Karmacharya P, Chakradhar R, Ogdie A. The epidemiology of psoriatic arthritis: A literature review. Best Pract Res Clin Rheumatol. 2021;35(2):101692. doi: 10.1016/j.berh.2021.101692
3. Khobeysh MM, Sokolovskiy EV. Systemic therapy of psoriasis and psoriatic arthritis: assignment algorithms. Vestnik dermatologii i venerologii. 2025;101(1):28–49 (In Russ.). doi: 10.25208/vdv16830
4. Mease PJ, Deodhar AA, van der Heijde D, Behrens F, Kivitz AJ, Neal J, Kim J, Singhal S, Nowak M, Banerjee S. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann Rheum Dis. 2022;81(6):815–822. doi: 10.1136/annrheumdis-2021-221664
5. Proft F, Lucas Ribeiro A, Singla S, Chandran V, Liao W, Lindsay C, Soriano ER, Bhutani T, Deodhar A, de Vlam K, Eder L, Kishimoto M, Leung YY, Lubrano E, McGonagle D, Poddubnyy D, Savage L, van den Bosch F, Mease PJ. Op0175Establishing Definitions For Difficult-To-Treat Psoriatic Arthritis (D2t-PsA) And Complex-To-Manage Psoriatic Arthritis (C2M-PsA): Insights from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (Grappa) Initiative. Annals of the Rheumatic Diseases. 2025;84(1):143–145. doi: 10.1016/j.ard.2025.05.188
6. Kristensen LE, Keiserman M, Papp K, McCasland L, White D, Lu W, Soliman AM, Eldred A, Barcomb L, Behrens F. Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study. Rheumatology. 2023;62(6):2113–2121. doi: 10.1093/rheumatology/keac607
Review
For citations:
Sinenko A.A., Lupach N.M., Syusina O.I., Zinkova E.A. Refractory psoriatic arthritis: A clinical case study of successful risankizumab therapy. Pacific Medical Journal. 2026;(1):83-86. (In Russ.) https://doi.org/10.34215/1609-1175-2026-1-83-86
Views:
133
JATS XML
Email this article 